scanx.trade

TherapeuticsMD Q2 EPS Drops 80% as Sales Decline and Milestone Payment Awaits

TherapeuticsMD logoTherapeuticsMD
Sig2.55Sen-5.35Env0.00Soc0.00Gov0.00

TherapeuticsMD reported net income from continuing operations of $164 thousand in Q2 2026, down $381 thousand (about 70%) versus Q2 2025. Total sales fell to $869 thousand, an 8.72% drop, and license revenue from continuing operations decreased to $864 thousand. Operating expenses rose slightly, tightening margins, while the company expects a CAD 500 thousand (~$364.8 thousand) milestone payment in Q3 that provides a one-time boost but not an underlying reversal of declining recurring royalties.

Coverage (1)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro